Anna B Halpern1, Eva Culakova2, Roland B Walter3, Gary H Lyman4. 1. Hematology/Oncology Fellowship Program, Fred Hutchinson Cancer Research Center/University of Washington, Seattle. 2. Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington3Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington5Division of Hematology, Department of Medicine, University of Washington, Seattle6Department of Epidemiology, University of Washington, Seattle. 4. Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington3Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington4Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington7Division of Medical Oncology, Department of Medicine, University of Washington, Seattle.
Abstract
IMPORTANCE: Adults with acute myeloid leukemia (AML) commonly require support in the intensive care unit (ICU), but risk factors for admission to the ICU and adverse outcomes remain poorly defined. OBJECTIVE: To examine risk factors, mortality, length of stay, and cost associated with admission to the ICU for patients with AML. DESIGN, SETTING, AND PARTICIPANTS: This study extracted information from the University HealthSystem Consortium database on patients 18 years or older with AML who were hospitalized for any cause between January 1, 2004, and December 31, 2012. The University HealthSystem Consortium database contains demographic, clinical, and cost variables prospectively abstracted by certified coders from discharge summaries. Outcomes were analyzed using univariate and multivariable statistical techniques. Data analysis was performed from November 15, 2013, to August 15, 2016. MAIN OUTCOMES AND MEASURES: Primary outcomes were admission to the ICU and inpatient mortality among patients requiring ICU care. Secondary outcomes included length of stay in the ICU, total hospitalization length of stay, and cost. RESULTS: Of the 43 249 patients with AML (mean [SD] age, 59.5 [16.6] years; 23 939 men and 19 310 women), 11 277 (26.1%) were admitted to the ICU. On multivariable analysis (with results reported as odds ratios [95% CIs]), independent risk factors for admission to the ICU included age younger than 80 years (1.56 [1.42-1.70]), hospitalization in the South (1.81 [1.71-1.92]), hospitalization at a low- or medium-volume hospital (1.25 [1.19-1.31]), number of comorbidities (10.64 [8.89-12.62] for 5 vs none), sepsis (4.61 [4.34-4.89]), invasive fungal infection (1.24 [1.11-1.39]), and pneumonia (1.73 [1.63-1.82]). In-hospital mortality was higher for patients requiring ICU care (4857 of 11 277 [43.1%] vs 2959 of 31 972 [9.3%]). On multivariable analysis, independent risk factors for death in patients requiring ICU care included age 60 years or older (1.16 [1.06-1.26]), nonwhite race/ethnicity (1.18 [1.07-1.30]), hospitalization on the West coast (1.19 [1.06-1.34]), number of comorbidities (18.76 [13.7-25.67] for 5 vs none), sepsis (2.94 [2.70-3.21]), invasive fungal infection (1.20 [1.02-1.42]), and pneumonia (1.13 [1.04-1.24]). Mean costs of hospitalization were higher for patients requiring ICU care ($83 354 vs $41 973) and increased with each comorbidity, from $50 543 for patients with no comorbidities to $124 820 for those with 5 or more comorbidities. CONCLUSIONS AND RELEVANCE: Admission to the ICU is associated with high mortality and cost that increase proportionally with the comorbidity burden in adults with AML. Several demographic factors and medical characteristics identify patients at risk for admission to the ICU and mortality and provide an opportunity for testing primary prevention strategies.
IMPORTANCE: Adults with acute myeloid leukemia (AML) commonly require support in the intensive care unit (ICU), but risk factors for admission to the ICU and adverse outcomes remain poorly defined. OBJECTIVE: To examine risk factors, mortality, length of stay, and cost associated with admission to the ICU for patients with AML. DESIGN, SETTING, AND PARTICIPANTS: This study extracted information from the University HealthSystem Consortium database on patients 18 years or older with AML who were hospitalized for any cause between January 1, 2004, and December 31, 2012. The University HealthSystem Consortium database contains demographic, clinical, and cost variables prospectively abstracted by certified coders from discharge summaries. Outcomes were analyzed using univariate and multivariable statistical techniques. Data analysis was performed from November 15, 2013, to August 15, 2016. MAIN OUTCOMES AND MEASURES: Primary outcomes were admission to the ICU and inpatient mortality among patients requiring ICU care. Secondary outcomes included length of stay in the ICU, total hospitalization length of stay, and cost. RESULTS: Of the 43 249 patients with AML (mean [SD] age, 59.5 [16.6] years; 23 939 men and 19 310 women), 11 277 (26.1%) were admitted to the ICU. On multivariable analysis (with results reported as odds ratios [95% CIs]), independent risk factors for admission to the ICU included age younger than 80 years (1.56 [1.42-1.70]), hospitalization in the South (1.81 [1.71-1.92]), hospitalization at a low- or medium-volume hospital (1.25 [1.19-1.31]), number of comorbidities (10.64 [8.89-12.62] for 5 vs none), sepsis (4.61 [4.34-4.89]), invasive fungal infection (1.24 [1.11-1.39]), and pneumonia (1.73 [1.63-1.82]). In-hospital mortality was higher for patients requiring ICU care (4857 of 11 277 [43.1%] vs 2959 of 31 972 [9.3%]). On multivariable analysis, independent risk factors for death in patients requiring ICU care included age 60 years or older (1.16 [1.06-1.26]), nonwhite race/ethnicity (1.18 [1.07-1.30]), hospitalization on the West coast (1.19 [1.06-1.34]), number of comorbidities (18.76 [13.7-25.67] for 5 vs none), sepsis (2.94 [2.70-3.21]), invasive fungal infection (1.20 [1.02-1.42]), and pneumonia (1.13 [1.04-1.24]). Mean costs of hospitalization were higher for patients requiring ICU care ($83 354 vs $41 973) and increased with each comorbidity, from $50 543 for patients with no comorbidities to $124 820 for those with 5 or more comorbidities. CONCLUSIONS AND RELEVANCE: Admission to the ICU is associated with high mortality and cost that increase proportionally with the comorbidity burden in adults with AML. Several demographic factors and medical characteristics identify patients at risk for admission to the ICU and mortality and provide an opportunity for testing primary prevention strategies.
Authors: Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: William M Townsend; Ailsa Holroyd; Rachel Pearce; Stephen Mackinnon; Prakesh Naik; Anthony H Goldstone; David C Linch; Karl S Peggs; Kirsty J Thomson; Mervyn Singer; David C J Howell; Emma C Morris Journal: Br J Haematol Date: 2013-03-18 Impact factor: 6.998
Authors: Stephen A Rawlings; Sven Heldt; Juergen Prattes; Susanne Eigl; Jeffrey D Jenks; Holger Flick; Jasmin Rabensteiner; Florian Prüller; Albert Wölfler; Peter Neumeister; Heimo Strohmaier; Robert Krause; Martin Hoenigl Journal: Front Immunol Date: 2019-08-02 Impact factor: 7.561
Authors: Anna B Halpern; Megan Othus; Emily M Huebner; Bart L Scott; Pamela S Becker; Mary-Elizabeth M Percival; Paul C Hendrie; Kelda M Gardner; Tara L Chen; Sarah A Buckley; Kaysey F Orlowski; Asma Anwar; Frederick R Appelbaum; Harry P Erba; Elihu H Estey; Roland B Walter Journal: Leukemia Date: 2018-04-17 Impact factor: 11.528
Authors: Lih-Wen Mau; Christa Meyer; Linda J Burns; Wael Saber; Patricia Steinert; David J Vanness; Jaime M Preussler; Alicia Silver; Susan Leppke; Elizabeth A Murphy; Ellen Denzen Journal: JNCI Cancer Spectr Date: 2019-08-28